Crossmark

Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models

Crossref DOI link: https://doi.org/10.1016/j.tranon.2017.06.003

Published Print: 2017-08

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Ugolkov, Andrey

Qiang, Wenan

Bondarenko, Gennadiy

Procissi, Daniel

Gaisina, Irina

James, C. David

Chandler, James

Kozikowski, Alan

Gunosewoyo, Hendra

O'Halloran, Thomas

Raizer, Jeffrey

Mazar, Andrew P.
Funding

Funding for this research was provided by:

Northwestern University Pathology Core Facility

Cancer Center Support (NCI CA060553)
License Information

Text and Data Mining valid from 2017-08-01

Text and Data Mining valid from 2017-08-01

Version of Record valid from 2017-03-04
More Information

This article is maintained by: Elsevier

Article Title: Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models

Journal Title: Translational Oncology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.tranon.2017.06.003

Content Type: article

Copyright: © 2017 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.